Managing Vesicant Extravasations
13-3-284_Schulmeister
|
CME Activity Information |
|
Release Date: |
April 7, 2008 |
|
Most Recent Review: |
April 7, 2008* |
|
Most Recent Update: |
April 7, 2008 |
|
Date Credit Expires: |
April 7, 2010 |
|
Time to Complete: |
1 hour |
|
Medium: |
Internet Online |
|
*Click here
to learn more about our review process. |
Instructions for Participation
- Read the following information before beginning the educational activity
and click the "Take this course" link at the bottom of the page
- Study the educational activity
- Complete the CME quiz and evaluation
- After successful completion of the CME quiz and evaluation, you will receive
the credit or participation certificate
*The CME quiz and evaluation must be completed by April 7, 2010, in order
to receive the credit or participation certificate.
Target Audience
Physicians who wish to advance their current knowledge of clinical cancer medicine
in the community oncology setting.
Learning Objectives
After completing this course, the reader should be able to:
- Describe how vesicant chemotherapy drugs can extravasate from implanted
ports.
- Recommend procedures to obtain a blood return from central venous access
devices.
- Evaluate the signs and symptoms of a vesicant extravasation.
- Administer the FDA-approved vesicant extravasation treatments and antidotes.
Accreditation and Credit Designation
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of the School of Medicine
of The University of North Carolina at Chapel Hill and The Oncologist.
The School of Medicine of The University of North Carolina at Chapel Hill is accredited
by the ACCME to provide continuing medical education for physicians.
The School of Medicine of The University of North Carolina at Chapel Hill designates
this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™.
Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Disclosure Policy
In compliance with the ACCME Standards of Commercial Support, it is the policy
of the School of Medicine of The University of North Carolina at Chapel Hill to
ensure balance, independence, objectivity, and scientific rigor in all of its
educational activities and to include information free of commercial bias and
based on the best evidence available. All individuals in a position to influence
the content of this activity have disclosed relevant financial interests or relationships
of their own, their spouse/partner, or their worksite, with manufacturers or providers
of commercial products, services, technology, or programs; and disclosed relationships
with current non-governmental supporters of the activity. The faculty and planners
have disclosed that they have no relevant commercial relationships.
All information is submitted and reviewed and found to be scientifically rigorous,
based on the best available evidence, fair and balanced, and free of commercial
bias. All the recommendations involving clinical medicine in this CME activity
are based on evidence that is accepted within the profession of medicine as
adequate justification for their indications and contraindications in the care
of patients. All scientific research referred to, reported or used in CME in
support or justification of a patient care recommendation conforms to the generally
accepted standards of experimental design, data collection and analysis.
Any potential conflicts of interests are resolved via The Oncologist's anonymous
peer review process: http://cme.theoncologist.com/misc/edboard.shtml.
All manuscripts are reviewed by the Editorial Board with ad hoc assistance from
two or more external experts in the field. All activity planners, authors, and
reviewers are required to submit conflict of interest forms. These forms accompany
the activity through the peer review process. Any reviewers who have a conflict
of interest are recused. When a reviewer is recused, other suitable reviewers
with no self-reported conflicts of interests are selected to conduct the reviews.
All final publication decisions are made by the Editorial Board. The acceptance
of a manuscript is based on its originality and importance to the field as assessed
by the Editors.
Author Disclosure(s)
Lisa Schulmeister, R.N., M.N., A.P.R.-N.B.C., O.C.N.®, F.A.A.N.
Credentials: Oncology Nursing Consultant, River Ridge,
Louisiana, USA.
Disclosures: The author has acted as a consultant to TopoTarget
USA (manufacturer of Totect™, which is mentioned in this article), and
has received an honorarium from Baxter (manufacturer of Hylenex®, which is
mentioned in this article) for participation in a focus
group.
Commercial Support
Non-governmental supporters of this activity: Abraxis BioScience,
AstraZeneca, Bristol-Myers Squibb Oncology, Merck, Pfizer, and sanofi-aventis
Hardware/Software Requirements
The Oncologist CME Online supports
the following browsers: Current production versions of Opera, Safari, Firefox,
Lynx and Mozilla; Netscape 6.1 and above, and Explorer 6.0 and above. The Macintosh
version of Explorer was discontinued in June 2003, and is not supported.
Other Links
Disclaimer
Privacy statement
Correspondence
The Oncologist CME Online
c/o AlphaMed Press
318 Blackwell Street, Suite 260
Durham, North Carolina 27701
Phone: (919) 680-0011
Fax: (919) 680-4411
Email: angela.davies{at}ucdmc.ucdavis.edu
Copyright © 2008 by AlphaMed Press.